AbbVie Inc. $ABBV Stock Position Raised by Freemont Management S.A.

Freemont Management S.A. lifted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 1,030.0% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 11,300 shares of the company’s stock after purchasing an additional 10,300 shares during the quarter. Freemont Management S.A.’s holdings in AbbVie were worth $2,582,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of ABBV. Rayburn West Financial Services LLC bought a new position in AbbVie in the 4th quarter worth about $4,026,000. Cardinal Point Capital Management ULC raised its holdings in shares of AbbVie by 4.6% during the fourth quarter. Cardinal Point Capital Management ULC now owns 6,870 shares of the company’s stock valued at $1,570,000 after buying an additional 300 shares during the last quarter. Atria Investments Inc raised its holdings in shares of AbbVie by 0.7% during the fourth quarter. Atria Investments Inc now owns 168,667 shares of the company’s stock valued at $38,539,000 after buying an additional 1,159 shares during the last quarter. Catalyst Financial Partners LLC boosted its position in shares of AbbVie by 5.8% during the fourth quarter. Catalyst Financial Partners LLC now owns 14,233 shares of the company’s stock worth $3,252,000 after buying an additional 785 shares during the period. Finally, Moneco Advisors LLC boosted its position in shares of AbbVie by 5.2% during the fourth quarter. Moneco Advisors LLC now owns 18,164 shares of the company’s stock worth $4,150,000 after buying an additional 892 shares during the period. Institutional investors own 70.23% of the company’s stock.

AbbVie Trading Up 0.3%

Shares of NYSE ABBV opened at $208.39 on Thursday. AbbVie Inc. has a twelve month low of $176.57 and a twelve month high of $244.81. The company has a market capitalization of $368.17 billion, a price-to-earnings ratio of 102.65, a PEG ratio of 0.72 and a beta of 0.32. The firm has a 50-day moving average of $211.23 and a two-hundred day moving average of $220.29.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. During the same period in the prior year, the company earned $2.46 EPS. AbbVie’s revenue was up 12.4% on a year-over-year basis. As a group, research analysts predict that AbbVie Inc. will post 14.32 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio is presently 340.89%.

Insider Transactions at AbbVie

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

ABBV has been the topic of several analyst reports. Royal Bank Of Canada started coverage on AbbVie in a research report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 target price on the stock. The Goldman Sachs Group reiterated a “neutral” rating and set a $223.00 price target on shares of AbbVie in a research report on Wednesday, January 28th. Canaccord Genuity Group increased their price target on AbbVie from $262.00 to $265.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Citigroup lowered their price target on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a report on Tuesday, January 27th. Finally, William Blair reaffirmed an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and an average target price of $252.90.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New immunology data and an upgraded 2026 earnings outlook are reinforcing confidence in AbbVie’s growth trajectory and valuation. A Look At AbbVie (ABBV) Valuation After New Immunology Data And Upgraded 2026 Earnings Outlook
• Positive Sentiment: Analyst commentary continues to lean constructive, with recent coverage highlighting AbbVie as an attractive long-term healthcare name and pointing to a higher price target from Evercore ISI. Why AbbVie Inc. (ABBV) is One of the Best Healthcare Stocks to Buy for the Long Term
• Positive Sentiment: Multiple recent articles argue AbbVie’s growth engine is “firing,” with bullish takes centered on its expanding drug portfolio and rising dividend, both supportive of investor sentiment. 3 Reasons to Buy AbbVie Stock (ABBV) Like There’s No Tomorrow
• Neutral Sentiment: AbbVie appointed Kelly Sanderson Schrems as UK VP and General Manager, a routine leadership move that is unlikely to materially move the stock on its own. AbbVie Appoints Kelly Sanderson Schrems as UK VP and General Manager
• Neutral Sentiment: Shareholders backed directors and maintained the governance structure at the annual meeting, which removes uncertainty but is not a major new catalyst. AbbVie Shareholders Back Directors, Maintain Governance Structure
• Neutral Sentiment: Zacks and other commentary remain supportive, but this is mostly reinforcing existing optimism rather than introducing a major new catalyst. The Zacks Analyst Blog NVIDIA, Mastercard, AbbVie, Waterstone and Precipio

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.